Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes - Aronson, R; Gottlieb, P A; Christiansen, J S (Diabetes Care, 2014)